219 related articles for article (PubMed ID: 36138026)
1. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
2. MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression.
Marona P; Górka J; Mazurek Z; Wilk W; Rys J; Majka M; Jura J; Miekus K
Cancer Res; 2017 Sep; 77(18):4905-4920. PubMed ID: 28716897
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
[TBL] [Abstract][Full Text] [Related]
4. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.
Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG
Cancer Lett; 2024 Jul; 593():216963. PubMed ID: 38768682
[TBL] [Abstract][Full Text] [Related]
5. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
6. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
[TBL] [Abstract][Full Text] [Related]
8. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
9. The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.
Wang Y; Peng M; Zhong Y; Xiong W; Zhu L; Jin X
Oncogene; 2023 Mar; 42(13):952-966. PubMed ID: 36732658
[TBL] [Abstract][Full Text] [Related]
10. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
[TBL] [Abstract][Full Text] [Related]
12. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
[TBL] [Abstract][Full Text] [Related]
13. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
[TBL] [Abstract][Full Text] [Related]
14. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
18. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
19. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
20. MCPIP1 inhibits Wnt/β-catenin signaling pathway activity and modulates epithelial-mesenchymal transition during clear cell renal cell carcinoma progression by targeting miRNAs.
Gorka J; Marona P; Kwapisz O; Waligórska A; Pospiech E; Dobrucki JW; Rys J; Jura J; Miekus K
Oncogene; 2021 Dec; 40(50):6720-6735. PubMed ID: 34657130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
